E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin Mesylate
Drug: Capecitabine

Registration Number: NCT00337103

Lead Sponsor: Eisai Inc.

Brief Summary: The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 1276

Inclusion Criteria

Female patients with histologically or cytologically confirmed carcinoma of the breast. Every effort should be made to ensure that paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen are available for confirmation of diagnosis.
Patients with locally advanced or metastatic disease who have received up to three prior chemotherapy regimens, and no more than two prior regimens for advanced and/or metastatic disease.
- Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel), either in combination or in separate regimens.
- Patients with known human epidermal growth factor 2 (HER2/neu) over-expressing tumors may additionally have been treated with trastuzumab in centers where this treatment is available.
- Patients with known estrogen and/or progesterone receptor-expressing tumors may have additionally been treated with hormonal therapy.
Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy <= Grade 2 and alopecia.
Age >= 18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
Life expectancy of >= 3 months.
Adequate renal function as evidenced by serum creatinine <1.5 mg/dL or calculated creatinine clearance > 50 mL/minute (min) per the Cockcroft and Gault formula.
Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin < 10.0 g/dL acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.
Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), or in case of bone metastases, liver specific alkaline phosphatase <= 3 x ULN.
Patients willing and able to complete the EORTC (European Organization for Research on the Treatment of Cancer) quality of life questionnaire (QLQ-C30 with breast cancer module QLQ-BR23) and to record their pain level on the Visual Analog Scale (VAS).
Patients willing and able to comply with the study protocol for the duration of the study.
Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria

Patients who have received more than three prior chemotherapy regimens for their disease, including adjuvant therapies, or patients who have received more than two prior chemotherapy regimens for advanced disease (other therapies are allowed e.g., anti-estrogens, trastuzumab and radiotherapy).
Patients who have received capecitabine as a prior therapy for their disease.
Patients who have received chemotherapy, radiation, or biological therapy within two weeks, or hormonal therapy, within one week before study treatment start, or any investigational drug within four weeks before study treatment start.
Radiation therapy encompassing > 30% of marrow.
Prior treatment with mitomycin C or nitrosourea.
Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment with study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced Computed Tomography Scan (CT) or Magnetic Resonance Imaging (MRI) brain scan performed during screening to a prior scan performed at least 4 weeks earlier.
Patients with meningeal carcinomatosis.
Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy, are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT)/international normalized ratio (INR) must be closely monitored.
Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception (considered to be two methods of contraception, one of which must be a barrier method, e.g. condom, diaphragm or cervical cap). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
Severe/uncontrolled intercurrent illness/infection.
Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association [NYHA] Grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).
Patients with organ allografts requiring immunosuppression.
Patients with known positive human immunodeficiency virus (HIV) status.
Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence.
Patients with pre-existing neuropathy > Grade 2.
Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.
Patients who participated in a prior E7389 clinical trial.
Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Eribulin Mesylate	-
2	Capecitabine	-

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS)	From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years	OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff.
Progression Free Survival (PFS)	From date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years	PFS was defined as the time (in days) from the date of randomization to the date of the first sign of disease progression based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (v 1.1) or date of death, regardless of cause. Disease progression was measured by computed tomography (CT) and magnetic resonance imaging (MRI) performed on lesions targeted at baseline for tumor assessment. Disease progression (as assessed by independent review of the imaging scans) per RECIST v 1.1 was defined as at least a 20% increase in the sum of the diameters of the target lesions (taking as reference the smallest sum on study, including the baseline sum if that is the smallest), and an absolute increase of at least 5 millimeter (mm). Note that the appearance of one or more new lesions was also considered as disease progression.

Secondary Outcome Measures

Name	Time	Method
Overall Survival Rate	From the date of randomization to Year 1, 2 and 3	One-, two-, and three- year's survival rates were defined as the percentage of participants who were alive at one, two, and three years respectively, and estimated using the Kaplan-Meier method and Greenwood Formula.
Change From Baseline in Pain Intensity by Visual Analog Scale (VAS) Until 30 Days After the Last Dose of Study Drug	First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)	Pain intensity was measured by marking a single vertical line that crosses a 1-100 mm unmarked VAS scale. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.
Number of Participants With Consumption of Analgesics During the Study	First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)	Participants took analgesics as concomitant pain medications which are defined as pain medications that (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on/after the day of the first dose of study drug up to 30 days after the last dose of study drug medication
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)	TEAEs included both SAEs as well as non-SAEs.
Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Core 30 Items (EORTC-QLQ-C30) at Week 6	Baseline and Week 6	EORTC-QLQ-C30:cancer-specific instrument with 30 questions to assess the participant QoL. First 28 questions used to evaluate 5 functional scales (physical, role, cognitive, emotional, social), 3 symptom scales (fatigue, nausea and vomiting, pain) and other single items(dyspnoea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Each of these 28 questions assessed on 4-point scale(1=not at all, 2=a little, 3=quite a bit, 4=very much); functional scales: higher score=better level of functioning; symptom scale: higher score=more severe symptoms; for single items: higher score= more severe problem. Last 2 questions used to evaluate global health status (GHS)/QoL. Each question was assessed on 7-point scale (1=very poor to 7=excellent). Scores averaged, transformed to 0-100 scale; higher score=better quality of life/better level of functioning.
Change From Baseline in European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Breast Cancer Specific 23 Items (EORTC-QLQ- BR 23) at Week 6	Baseline and Week 6	EORTC-QLQ-BR23:disease-specific module for breast cancer developed as a supplement for the EORTC-QLQ-C30 to assess quality of life of participants with breast cancer. The scores from 23 items of QLQ-BR23 included functional scales (body image, sexual functioning, sexual enjoyment, future perspective), symptom scales (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated on a scale of 1 to 4 to record level of intensity (1= not at all, 2= a little, 3= quite a bit, 4= very much) within each scales. Scores averaged and transformed to 0-100 scale. High score indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
Objective Response Rate (ORR): Independent Review	From date of randomization until date of first documentation of CR or PR, assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years	ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v 1.1). CR is defined as disappearance of all target legions and non-target lesions. All pathological lymph nodes (whether target and non-target), must have reduction in their short axis to less than 10 mm. PR is defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
Duration of Response (DOR): Independent Review	From first documented CR or PR until date of recurrent or progressive disease or death, assessed up to data cutoff of date of 12 Mar 2012 or up to approximately 6 years	DOR was defined as the time from first documented CR or PR until disease progression or death from any cause for those participants with a confirmed PR or CR measured by RECIST v1.1. CR defined as disappearance of all target and non-target lesions. All pathological lymph nodes(whether target and non-target), must have reduction in their short axis to less than 10 mm. PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Parameter Values	First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)
Number of Participants Who Took at Least One Concomitant Medication	First dose of study drug (Baseline) up to 30 days after last dose of study drug (up to approximately 6 years 3 months)	Concomitant medications included medications that either (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on or after the first dose of study drug up to 30 days after the last dose of study drug.
Duration of Eribulin Mesylate Exposure	Up to approximately 6 years for primary analysis completion stage, Up to approximately 6 years 2 months for final analysis completion stage	Data have been reported per primary analysis completion stage and final analysis completion stage. After primary analysis completion (at cutoff date of 12 March 2012), only 10 participants were still receiving study treatment.
Plasma Concentrations of Eribulin Mesylate	Cycle 1 Day 1: 5-10 minutes(min), 15-30 min, 30-60 min, 60-90 min, 2-4 hours(hrs), 4-8 hrs, 10-24 hrs, 48-72 hrs, 72-96 hrs, 96-120 hrs after the start of infusion of Eribulin mesylate (Duration of each cycle is 21 days)

Trial Locations

Locations (68): Institut Jules Bordet, Medical Oncology Unit
🇧🇪
Brussels, Belgium
Royal Perth Hospital
🇦🇺
Perth, Western Australia, Australia
Bankstown Hospital, Oncology Trials Unit
🇦🇺
Bankstown, New South Wales, Australia
Hospital Italiano de Buenos Aires
🇦🇷
Ciudad Autonoma de Buenos Aires, Argentina
Pecsi Tudomanyegyetem, Onkoterapias Intezet
🇭🇺
Pecs, Hungary
Centre Hosptialier Universitaire Sart Tilman Liege
🇧🇪
Liege, Belgium
Associacao Hospital de Caridade Ijui
🇧🇷
Ijui, Brazil
Mater Adult Hospital
🇦🇺
South Brisbane, Australia
Hospital de Clinicas de Porto Alegre, Servicio de Oncologia
🇧🇷
Porto Alegre, Brazil
Hospital Nossa Senhora da Conceicao
🇧🇷
Porto Alegre, Brazil
Hospital do Cancer de Sao Paulo-AC. Camargo
🇧🇷
Sao Paulo, Brazil
Corporacion Medica General San Martin
🇦🇷
San Martin, Buenos Aires, Argentina
Nucleo de Oncologia da Bahia
🇧🇷
Salvador, Brazil
Onkologicka Klinika, Fakutni Nemocnice
🇨🇿
Olomouc, Czechia
Hopital du Sacre-Coeur de Montreal
🇨🇦
Montreal, Quebec, Canada
Instituto Argentino de Diagnostico y Tratamiento
🇦🇷
Cuidad Autonoma de Buenos Aires, Buenos Aires, Argentina
Thunder Bay Regional Health Science Centre Northwestern Ontario
🇨🇦
Thunder Bay, Canada
Krajska nemocnice T. Bati
🇨🇿
Zlin Poiters, Czechia
Epworth Freemasons Hospital
🇦🇺
East Melbourne, Australia
Proonco Centro de Tratamento Oncologico
🇧🇷
Londrina, Brazil
OLVZ Aalst, Oncology Service
🇧🇪
Aalst, Belgium
Augusta-Kranken-Anstalt, Klinik fur Hamatologie und Onkologie
🇩🇪
Bochum, Germany
Hospital das Clinicas de Faculdade de Medicina da Universidade de Sao
🇧🇷
Sao Paulo, Brazil
Centre Hospitalier Universitaire de Montreal, Hopital Notre Dame
🇨🇦
Montreal, Canada
1. LF UK, Ustav radiacnej onkologie
🇨🇿
Prague 8, Czechia
Servico de Quimioterapia de Pernambuco-SEQUIPE
🇧🇷
Recife, Brazil
Universitatsfrauenklinik Magdeburg
🇩🇪
Magdeburg, Germany
Sharet Institute of Oncology
🇮🇱
Jerusalem, Israel
Debrecen University
🇭🇺
Debrecen, Hungary
Algemeen Ziekenhuis Sint Lucas
🇧🇪
Ghent, Belgium
Instituto Ribeiraopretano de Combate ao Cancer
🇧🇷
Ribeirao Preto, Brazil
Soroka Medical Center
🇮🇱
Beer Sheva, Israel
Barzilai Medical Center
🇮🇱
Ashkelon, Israel
Sir Charles Gairdner Hospital, Dept. of Medical Oncology
🇦🇺
Nedlands, Australia
Spitalul Militar Central Bucuresti
🇷🇴
Bucharest, Romania
Kaplan Medical Center
🇮🇱
Rechovot, Israel
Unita Operativa de Oncologia
🇮🇹
Lugo, Italy
Centro Estatal de Cancerologia
🇲🇽
Chihuahua, Mexico
Regionalny Osrodek Onkologii
🇵🇱
Bialystok, Poland
The Chaim Sheba Medical Center
🇮🇱
Tel Hashomer, Israel
Consultorio del Dr. Trigueros
🇲🇽
Morelia, Mexico
Azienda Ospedaliera San Salvatore
🇮🇹
Pesaro, Italy
Liverpool Hospital, Cancer Therapy Centre
🇦🇺
Liverpool, New South Wales, Australia
Ashford Cancer Centre
🇦🇺
Adelaide, South Australia, Australia
Saint Vincent's Hospital
🇦🇺
Fitzroy, Victoria, Australia
UO di Onco-ematologia
🇮🇹
Rimini, Italy
Faculdade de Medicina do ABC
🇧🇷
Santo Andre, Brazil
Grupo Paulista de Oncologia Integrada Ltda
🇧🇷
Sao Paulo, Brazil
Hospital do Cancer de Sao Paulo-AC Camargo
🇧🇷
Sao Paulo, Brazil
Centre Hospitalier La Roche sur Yon, CHD les Oudairies
🇫🇷
La Roche sur Yon, France
CHU de Poitiers, Service d'Oncologie Medicale
🇫🇷
Poitiers Cedex, France
Hopital Nord Saint-Etienne
🇫🇷
Saint Priest en Jarez, France
Rabin Medical Center
🇮🇱
Petach Tikva, Israel
Hospital General de Agudos Teodoro Alvarez
🇦🇷
Ciudad Autonoma, Buenos Aires, Argentina
Instituto de Oncologia Ltda
🇧🇷
Jundiai, Brazil
Instituto Brasileiro de Controle do Cancer-IBCC
🇧🇷
Sao Paulo, Brazil
Montreal General Hospital
🇨🇦
Montreal, Quebec, Canada
Nemocnice Ceske Budejovice, a.s.
🇨🇿
Ceske Budejovice, Czechia
Meir Hospital, Sapir Medical Center
🇮🇱
Kfar Saba, Israel
Ospedale Civile S. Maria delle Croci
🇮🇹
Ravenna, Italy
Wojewodzkie Centrum Onkologii
🇵🇱
Gdansk, Poland
Spitalul Clinic Judetean Sibiu
🇷🇴
Sibiu, Romania
Blokhin Cancer Research Centre
🇷🇺
Moscow, Russian Federation
Regional Oncology Dispensary
🇷🇺
Yaroslavl, Yaroslavlr, Russian Federation
Panorama Medical Centre
🇿🇦
Cape Town, South Africa
Centrul de Oncologie Medicala
🇷🇴
Iasi, Romania
Royal Hobart Hospital
🇦🇺
Hobart, Tasmania, Australia
Wojewodzki Szpital Specjalistyczny
🇵🇱
Wroclaw, Poland